George Grunberger, MD, president of AACE stated in an updated consensus statement that, “The organization acknowledges that pumps have become more sophisticated, and in order to obtain maximum benefit, training programs should be developed.” According to that statement, which was published in Endocrine Practice, an update to earlier guidance from 2010 offered recommendations for patients who are on pump therapy with both type 1 and type 2 diabetes. Welchol is also indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. He is a Professor of Medicine on the voluntary faculty at the University of Miami. Some include the considerable variation in accuracy and precision between different manufacturers’ products, while others involve cost and access issues. In addition, the AACE position statement highlights the significant benefits of testosterone therapy in men with CV risk factors, including a decrease in fat mass, an increase in muscle mass, decreased insulin resistance and a reversal of metabolic syndrome in some patients. Several obesity experts contacted by MedPage Today said they agreed with the new guidance, that treating overweight and obesity could resolve many of the conditions that commonly occur with it. Clinicians diagnose prediabetes, or being at high risk for diabetes, when patients’ fasting glucose is between 100 and 125 mg/dL, glucose tolerance test is 140 to 199 mg/dL, and hemoglobin
It feels like just about every day we hear about another case of bladder cancer linked to Actos. Diabetic macular edema is an Actos side effect that can develop following cataract surgery, though the condition can develop in the absence of such surgery. In fact, there are currently 8,000 claims against the company across a number of states, with the next trial set to begin in March. Since 2007 when competing diabetes drug Avandia was shown to increase risk of heart attack, Actos sales have escalated, swelling to $4.3 billion in 2010. A recent Northern California study of 193,000 diabetic patients with Type 2 diabetes found that diabetics who took ACTOS had a 40% higher risk of developing bladder cancer than a control group. In June 2011, the FDA issued a safety announcement warning patients and healthcare providers about the increased risk of bladder cancer in patients who take Actos for longer than one year. [2011.11] CONCLUSIONS: Results from clinical trials and current safety data suggest that rosiglitazone should not be used for the treatment of AD.
Pioglitazone is now the second medication in the thiazolidinedione (TZD) class to be associated with serious side effects within the past year. Follow-ups were conducted at 1 and 10 years after the study index date. But if you’ve taken Actos, having yourself checked for bladder cancer might help you catch it early so you can get it taken care of before it becomes a problem. People on Invokana (Canagliflozin) can